Avalon GloboCare Corp. announced that it has appointed William B. Stilley to the company’s board of directors. In addition, Mr. Stilley will head the board’s audit committee. Mr. Stilley currently serves as Chief Executive Officer of Adial Pharmaceuticals Inc. Prior to joining Adial, he was the Vice President, Business Development & Strategic Projects at Clinical Data Inc. At Clinical Data Inc., Mr. Stilley worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd® for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the company’s vasodilator drug for myocardial stress imaging. Mr. Stilley also served as the COO and CFO of Adenosine Therapeutics, LLC where he ran the internal operations of the company, including research and development, and all financing activity, until the sale of its principal assets to Clinical Data Inc.